NICE approves expanded access to early breast cancer treatment
The National Institute for Health and Care Excellence (NICE) has recommended a combination treatment for early breast cancer that helps to prevent the disease returning. In final draft guidance published on 17 July 2025, NICE recommended ribociclib (Kisqali; Novartis) for the adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer, which has responded to initial […]
Publication Details
- Journal
- Pharmaceutical journal/The pharmaceutical journal
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1211/pj.2025.1.364888
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00